

Efficacy of cholesterol-lowering therapy in 18,868 people with diabetes in 14 randomised trials of statins: a meta-analysis

Lancet 2008 **371**: 117-125

[doi:10.1016/S0140-6736\(08\)60104-X](https://doi.org/10.1016/S0140-6736(08)60104-X)

Baseline characteristics of participants with diabetes (1)

Baseline feature	Diabetes Mellitus		
	Type 1 (n=1466)	Type 2 (n=17220)*	Any type (n=18686)
Age (years)	55.1 (10.7)	63.8 (8.4)	63.1 (8.9)
Men	67%	67%	67%
Smokers	21%	16%	16%
Vascular disease			
Any	56%	36%	37%
None	44%	64%	63%
Treated hypertension	48%	69%	67%
Systolic BP (mm Hg)	140.9 (21.9)	148.6 (20.9)	148.0 (21.1)
Body-mass Index (kg/m ²)	26.2 (4.3)	29.6 (13.6)	29.3 (13.2)


Data are mean (SD) or percentage. *Includes 13 participants with diabetes of unknown type.

Baseline characteristics of participants with diabetes (2)

Baseline feature	Diabetes Mellitus		
	Type 1 (n=1466)	Type 2 (n=17220)*	Any type (n=18686)
Total Cholesterol (mmol/L)	5.7 (1.0)	5.6 (0.9)	5.6 (0.9)
LDL Cholesterol (mmol/L)	3.4 (0.9)	3.4 (0.8)	3.4 (0.8)
HDL Cholesterol (mmol/L)	1.3 (0.4)	1.2 (0.4)	1.2 (0.4)
Triglycerides (mmol/L)	1.6 (1.0)	2.1 (1.3)	2.0 (1.2)

Data are mean (SD) or percentage. *Includes 13 participants with diabetes of unknown type.

Effects on CAUSE-SPECIFIC MORTALITY, per mmol/L reduction in LDL cholesterol, among patients with diabetes




Effects on MAJOR VASCULAR EVENTS, per mmol/L reduction in LDL cholesterol, among participants with diabetes

Major vascular event and prior diabetes	Events (%)		RR (CI)
	Treatment	Control	
Major coronary event			
Diabetes	776 (8.3)	979 (10.5)	0.78 (0.69 - 0.87)
No diabetes	2561 (7.2)	3441 (9.6)	0.77 (0.73 - 0.81)
Any major coronary event	3337 (7.4)	4420 (9.8)	0.77 (0.74 - 0.80)
Coronary revascularization			
Diabetes	491 (5.2)	627 (6.7)	0.75 (0.64 - 0.88)
No diabetes	2129 (6.0)	2807 (7.9)	0.76 (0.72 - 0.81)
Any coronary revascularization	2620 (5.8)	3434 (7.6)	0.76 (0.73 - 0.80)
Stroke			
Diabetes	407 (4.4)	501 (5.4)	0.79 (0.67 - 0.93)
No diabetes	933 (2.7)	1116 (3.2)	0.84 (0.76 - 0.93)
Any stroke	1340 (3.0)	1617 (3.7)	0.83 (0.77 - 0.88)
Major vascular event			
Diabetes	1465 (15.6)	1782 (19.2)	0.79 (0.72 - 0.86)
No diabetes	4889 (13.7)	6212 (17.4)	0.79 (0.76 - 0.82)
Any major vascular event	6354 (14.1)	7994 (17.8)	0.79 (0.77 - 0.81)


0.5 1.0 1.5

—■— RR (99% CI) ◇ RR (95% CI)


Effects on MAJOR VASCULAR EVENTS per mmol/L reduction in LDL cholesterol in participants with diabetes, by history of vascular disease



Effects on MAJOR VASCULAR EVENTS, per mmol/L reduction in LDL cholesterol, by baseline prognostic factors in participants with diabetes (1)




Effects on MAJOR VASCULAR EVENTS, per mmol/L reduction in LDL cholesterol, by baseline prognostic factors in participants with diabetes (2)



■ RR (99% CI) ◇ RR (95% CI)

Effects on MAJOR VASCULAR EVENTS, per mmol/L reduction in LDL cholesterol, by baseline lipid profile in participants with diabetes



Effects on MAJOR VASCULAR EVENTS, per mmol/L reduction in LDL cholesterol, by year

